DK1135513T3 - Adenovirus-medieret genterapi - Google Patents

Adenovirus-medieret genterapi

Info

Publication number
DK1135513T3
DK1135513T3 DK99971860T DK99971860T DK1135513T3 DK 1135513 T3 DK1135513 T3 DK 1135513T3 DK 99971860 T DK99971860 T DK 99971860T DK 99971860 T DK99971860 T DK 99971860T DK 1135513 T3 DK1135513 T3 DK 1135513T3
Authority
DK
Denmark
Prior art keywords
adenovirus
gene therapy
mediated gene
useful
treatment
Prior art date
Application number
DK99971860T
Other languages
English (en)
Other versions
DK1135513T4 (da
Inventor
Seppo Yla-Herttuala
Anu-Maaria Sandmair
Sami Loimas
Matti Vapalahti
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1135513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Application granted granted Critical
Publication of DK1135513T3 publication Critical patent/DK1135513T3/da
Publication of DK1135513T4 publication Critical patent/DK1135513T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK99971860.4T 1998-11-06 1999-11-05 Adenovirus-medieret genterapi DK1135513T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy
PCT/EP1999/009017 WO2000028059A1 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy

Publications (2)

Publication Number Publication Date
DK1135513T3 true DK1135513T3 (da) 2006-11-27
DK1135513T4 DK1135513T4 (da) 2011-11-21

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99971860.4T DK1135513T4 (da) 1998-11-06 1999-11-05 Adenovirus-medieret genterapi

Country Status (18)

Country Link
US (1) US6579855B1 (da)
EP (1) EP1135513B2 (da)
JP (1) JP4733833B2 (da)
KR (1) KR20020013473A (da)
CN (1) CN1184321C (da)
AT (1) ATE341639T1 (da)
AU (1) AU749451B2 (da)
CA (1) CA2348624C (da)
CY (1) CY1106198T1 (da)
DE (1) DE69933468T3 (da)
DK (1) DK1135513T4 (da)
ES (1) ES2273521T5 (da)
GB (1) GB9824437D0 (da)
HU (1) HUP0104046A3 (da)
NO (1) NO330776B1 (da)
PL (1) PL193076B1 (da)
PT (1) PT1135513E (da)
WO (1) WO2000028059A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
CA2863964C (en) 2012-02-07 2021-10-26 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US20160058888A1 (en) * 2013-05-08 2016-03-03 Gliotherapy Limited Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir
WO2015021443A1 (en) 2013-08-08 2015-02-12 Global Bio Therapeutics Usa, Inc. Clamp device for minimally invasive procedures and uses thereof
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
MX2022014239A (es) 2020-05-12 2023-02-09 Regeneron Pharma Nuevos agonistas de il10 y metodos para su uso.
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
TW202334223A (zh) 2021-11-11 2023-09-01 美商再生元醫藥公司 Ｃｄ２０－ｐｄ１結合分子及其使用方法
EP4649088A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
EP4649092A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
EP4709756A1 (en) 2023-05-10 2026-03-18 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
WO2025106469A1 (en) 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
ES2273521T3 (es) 2007-05-01
GB9824437D0 (en) 1999-01-06
KR20020013473A (ko) 2002-02-20
DK1135513T4 (da) 2011-11-21
CA2348624A1 (en) 2000-05-18
EP1135513A1 (en) 2001-09-26
WO2000028059A1 (en) 2000-05-18
US6579855B1 (en) 2003-06-17
DE69933468T3 (de) 2012-01-19
CN1325450A (zh) 2001-12-05
ATE341639T1 (de) 2006-10-15
ES2273521T5 (es) 2011-12-28
DE69933468D1 (de) 2006-11-16
HUP0104046A3 (en) 2003-09-29
CN1184321C (zh) 2005-01-12
CY1106198T1 (el) 2011-06-08
DE69933468T2 (de) 2007-01-11
NO20012220L (no) 2001-05-04
PT1135513E (pt) 2006-12-29
NO20012220D0 (no) 2001-05-04
NO330776B1 (no) 2011-07-11
PL193076B1 (pl) 2007-01-31
HUP0104046A2 (hu) 2002-01-28
CA2348624C (en) 2012-07-31
JP4733833B2 (ja) 2011-07-27
EP1135513B1 (en) 2006-10-04
JP2002529097A (ja) 2002-09-10
AU749451B2 (en) 2002-06-27
EP1135513B2 (en) 2011-08-10
AU1385100A (en) 2000-05-29
PL349489A1 (en) 2002-07-29

Similar Documents

Publication Publication Date Title
DK1135513T4 (da) Adenovirus-medieret genterapi
DE69735643D1 (de) IL12 zur Gentherapie der Tumoren
FI970768A7 (fi) Kasvainten geeniterapiahoito endoteelisoluspesifisellä, solusyklistä r iippuvalla vaikuttavalla aineella
JO2248B1 (en) Pirazolobenzodiazepines
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
NO20005885D0 (no) Kombinasjonsterapi for behandling av refraktær depresjon
AU3552399A (en) Recombinant poliovirus for the treatment of cancer
AU3891299A (en) Combination therapy for treatment of depression
AU1264200A (en) Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
DE59510240D1 (de) Hochfrequenztherapieeinrichtung zur interstitiellen Thermotherapie von Tumoren
FI962114A7 (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
NO20006047D0 (no) Fremgangsmåte for genterapi
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
HUP0101947A3 (en) Combination for the treatment of tumors
MXPA02001204A (es) Compuestos calciliticos.
EP0666313A3 (en) Telomerase as a target in cancer gene therapy.
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
IS5481A (is) Samsett meðferð til meðhöndlunar á alnæmi
EP1023459A4 (en) DETERMINATION OF EXISTING QUANTITIES OF CYCLINE-DEPENDENT KINASE INHIBITOR P27 AS A PROGNOSTIC FACTOR IN CANCER PATIENTS
AU5778399A (en) Gene therapy for treatment of cancer
EP1126879A4 (en) GENE THERAPY FOR REGULATING THE TONUS OF SMOOTH MUSCULAR
PT1064014E (pt) Medicamento para o impedimento ou tratamento de tumores especificos de papilomavirus
HU9700425D0 (en) Use of incubated, citrate-containing leukaemic blood-product for treating tumors
AU3329999A (en) Suicide gene therapy system for the treatment of brain tumours